Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
24.16
+0.71 (3.03%)
At close: Apr 28, 2026, 4:00 PM EDT
24.20
+0.04 (0.17%)
After-hours: Apr 28, 2026, 6:48 PM EDT
Eton Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 79.95 | 39.01 | 31.64 | 21.25 | 21.83 | |
| Revenue Growth (YoY) | 104.94% | 23.29% | 48.90% | -2.66% | 55879.49% | |
| Cost of Revenue | 32.12 | 15.6 | 10.58 | 6.93 | 2.83 | |
| Gross Profit | 47.83 | 23.41 | 21.06 | 14.32 | 19.01 | |
| Selling, General & Admin | 35.24 | 22.34 | 18.93 | 18.58 | 14.27 | |
| Research & Development | 7.77 | 3.26 | 3.32 | 4 | 6.23 | |
| Operating Expenses | 43 | 25.59 | 22.25 | 22.58 | 20.5 | |
| Operating Income | 4.83 | -2.18 | -1.19 | -8.26 | -1.5 | |
| Interest Expense | -4.78 | -2.01 | -1.06 | -0.96 | -1.04 | |
| Interest & Investment Income | 1.07 | 0.79 | 1.56 | 0.19 | 0.04 | |
| EBT Excluding Unusual Items | 1.12 | -3.39 | -0.69 | -9.02 | -2.5 | |
| Merger & Restructuring Charges | -5.68 | -0.42 | - | - | - | |
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.18 | |
| Other Unusual Items | - | - | - | - | 0.37 | |
| Pretax Income | -4.56 | -3.81 | -0.69 | -9.02 | -1.96 | |
| Income Tax Expense | 0.04 | 0.02 | 0.25 | - | - | |
| Net Income | -4.6 | -3.82 | -0.94 | -9.02 | -1.96 | |
| Net Income to Common | -4.6 | -3.82 | -0.94 | -9.02 | -1.96 | |
| Shares Outstanding (Basic) | 27 | 26 | 26 | 25 | 25 | |
| Shares Outstanding (Diluted) | 27 | 26 | 26 | 25 | 25 | |
| Shares Change (YoY) | 3.91% | 0.97% | 1.99% | -0.24% | 19.98% | |
| EPS (Basic) | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | |
| EPS (Diluted) | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | |
| Free Cash Flow | 10.19 | 0.94 | 6.82 | 4.78 | -4.73 | |
| Free Cash Flow Per Share | 0.38 | 0.04 | 0.27 | 0.19 | -0.19 | |
| Gross Margin | 59.83% | 60.01% | 66.56% | 67.38% | 87.05% | |
| Operating Margin | 6.04% | -5.59% | -3.77% | -38.87% | -6.85% | |
| Profit Margin | -5.75% | -9.80% | -2.96% | -42.45% | -8.96% | |
| Free Cash Flow Margin | 12.75% | 2.42% | 21.54% | 22.51% | -21.66% | |
| EBITDA | 8.88 | -1.04 | -0.29 | -6.49 | -1.12 | |
| EBITDA Margin | 11.10% | -2.66% | -0.92% | -30.52% | -5.13% | |
| D&A For EBITDA | 4.04 | 1.15 | 0.9 | 1.77 | 0.37 | |
| EBIT | 4.83 | -2.18 | -1.19 | -8.26 | -1.5 | |
| EBIT Margin | 6.04% | -5.59% | -3.77% | -38.87% | -6.85% | |
| Revenue as Reported | 79.95 | 39.01 | 31.64 | 21.25 | 21.83 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.